Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 330

The DOI matches its Crossref record; 169 of the 169 references it cites were found in a registry or an index.

Multilevel omics for the discovery of biomarkers and therapeutic targets for stroke

Open access
Montaner, Joan, Ramiro, Laura, Simats, Alba, Tiedt, Steffen, Makris, Konstantinos, Jickling, Glen C., Debette, Stephanie, Sanchez, Jean-Charles, Bustamante, Alejandro·2020·Nature Reviews Neurology

Abstract

Despite many years of research, no biomarkers for stroke are available to use in clinical practice. Progress in high-throughput technologies has provided new opportunities to understand the pathophysiology of this complex disease, and these studies have generated large amounts of data and information at different molecular levels. The integration of these multi-omics data means that thousands of proteins (proteomics), genes (genomics), RNAs (transcriptomics) and metabolites (metabolomics) can be studied simultaneously, revealing interaction networks between the molecular levels. Integrated analysis of multi-omics data will provide useful insight into stroke pathogenesis, identification of therapeutic targets and biomarker discovery. In this Review, we detail current knowledge on the pathology of stroke and the current status of biomarker research in stroke. We summarize how proteomics, metabolomics, transcriptomics and genomics are all contributing to the identification of new candidate biomarkers that could be developed and used in clinical stroke management. In this Review, Montaner and colleagues summarize how proteomics, genomics, transcriptomics and metabolomics are contributing to the discovery and development of biomarkers in stroke, and how bringing them together with integromics could provide new biomarkers and therapeutic opportunities. Biomarkers of stroke could improve diagnosis and management, but standardization or harmonization of procedures is needed before translation of biomarkers to clinical practice to ensure results are comparable and reliable. Studies of the proteome of the brain, cerebrospinal fluid and brain extracellular fluid after ischaemic stroke have led to identification of candidate biomarkers for stroke management. Most studies of stroke genetics have focused on common or low-frequency single-nucleotide polymorphisms; other types of variation, such as rare single-nucleotide variants or structural variations, have been insufficiently explored. Changes in RNA levels in stroke have the potential to aid stroke diagnosis and provide insight into stroke aetiology. Circulating metabolites provide information about local and systemic events after stroke, and therefore could serve as biomarkers of stroke and for differentiation of major stroke aetiologies. Integrated analysis of data obtained with different omics approaches will enable implementation of biomarkers at several stages in the stroke care pathway, with the potential to transform stroke management.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41582-020-0350-6

Cites

169 of 169 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 169 references

Research works printed but not linked: 14

  1. Wetterling, F. et al. Investigating potentially salvageable penumbra tissue in an in vivo model of transient ischemic stroke using sodium, diffusion, and perfusion magnetic resonance imaging. BMC Neurosci. 17, 1–10 (2016). · doi:10.1186/s12868-016-0316-1
  2. Shi, K., Wood, K., Shi, F. D., Wang, X. & Liu, Q. Stroke-induced immunosuppression and poststroke infection. Stroke Vasc. Neurol. 3, 34–41 (2018). · doi:10.1136/svn-2017-000123
  3. Montaner, J. et al. A panel of biomarkers including caspase-3 and D-dimer may differentiate acute stroke from stroke-mimicking conditions in the emergency department. J. Intern. Med. 270, 166–174 (2011). · doi:10.1111/j.1365-2796.2010.02329.x
  4. Bustamante, A. et al. Blood biomarkers for the early diagnosis of stroke: the Stroke-Chip study. Stroke 48, 2419–2425 (2017). This is the largest study of biomarkers in acute stroke diagnosis and provides promising candidates for future panels. · doi:10.1161/strokeaha.117.017076
  5. Yuan, R. et al. Predictive value of plasma matrix metalloproteinase-9 concentrations for spontaneous haemorrhagic transformation in patients with acute ischaemic stroke: a cohort study in Chinese patients. J. Clin. Neurosci. 58, 108–112 (2018). · doi:10.1016/j.jocn.2018.09.014
  6. Azurmendi, L. et al. Proteomic discovery and verification of serum amyloid A as a predictor marker of patients at risk of post-stroke infection: a pilot study. Clin. Proteomics 14, 27 (2017). · doi:10.1186/s12014-017-9162-0
  7. Bai, J., Sun, H., Xie, L., Zhu, Y. & Feng, Y. Detection of cardioembolic stroke with B-type natriuretic peptide or N-terminal pro-BNP: a comparative diagnostic meta-analysis. Int. J. Neurosci. 128, 1100–1108 (2018). · doi:10.1080/00207454.2017.1408612
  8. Okazaki, S. et al. Moyamoya disease susceptibility variant RNF213 p.R4810K increases the risk of ischemic stroke attributable to large-artery atherosclerosis. Circulation 139, 295–298 (2019). · doi:10.1161/circulationaha.118.038439
  9. Cole, J. W. et al. Genetics of the thrombomodulin–endothelial cell protein C receptor system and the risk of early-onset ischemic stroke. PLoS One 13, e0206554 (2018). · doi:10.1371/journal.pone.0206554
  10. Dorothea Pfeiffer, Bowang et al. Genetic imbalance is associated with functional outcome after ischemic stroke. Stroke 50, 298–304 (2019). · doi:10.1161/strokeaha.118.021856
  11. Wang, W. et al. Integrated analysis of lncRNA-mRNA co-expression profiles in patients with Moyamoya disease. Sci. Rep. 7, 42421 (2017). · doi:10.1038/srep42421
  12. Wang, J. et al. Predictive value of long noncoding RNA ZFAS1 in patients with ischemic stroke. Clin. Exp. Hypertens. 41, 615–621 (2018). · doi:10.1080/10641963.2018.1529774
  13. Kennedy, J. et al. Rapid screening and identification of novel psychoactive substances using PaperSpray interfaced to high resolution mass spectrometry. Clin. Mass Spectrom. 1, 3–10 (2016). · doi:10.1016/j.clinms.2016.08.003
  14. Land, W. H. et al. Partial least squares (PLS) applied to medical bioinformatics. Procedia Comput. Sci. 6, 273–278 (2011). · doi:10.1016/j.procs.2011.08.051

Cited by

See all 330

Metadata

Authors
Montaner, J., Ramiro, L., Simats, A., Tiedt, S., Makris, K., Jickling, G. C., Debette, S., Sanchez, J.-C., & Bustamante, A.
Venue
Nature Reviews Neurology
Published
2020-04-22
Volume
16
Issue
5
Pages
247-264
ISSN
  • 1759-4758 (ISSN-L)
  • 1759-4766
OpenAlex
W3017710116
Cited by
330
References
169
FWCI
9.18
Type
journal article
Language
en
Open access
green
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Multilevel omics for the discovery of biomarkers and therapeutic targets for stroke. https://app.cochat.ai/papers/10.1038/s41582-020-0350-6
The paper
Montaner, J., Ramiro, L., Simats, A., Tiedt, S., Makris, K., Jickling, G. C., Debette, S., Sanchez, J.-C., & Bustamante, A. (2020). Multilevel omics for the discovery of biomarkers and therapeutic targets for stroke. Nature Reviews Neurology. https://doi.org/10.1038/s41582-020-0350-6

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.